# When will retatrutide be approved? · PepVault guides

Source: https://pepvault.app/guides/when-will-retatrutide-be-approved

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# When will retatrutide be approved?

Reviewed November 2026 22 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Retatrutide isn't approved yet. Lilly plans to file with the FDA in early 2027. The review clock, the phase 3 dates and the court case, as of November 2026.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 22
- **Questions:** 7
- **Compounds:** 2

## The short answer

As of November 2026, no regulator has approved retatrutide. Eli Lilly plans to file with the FDA in the first quarter of 2027. The FDA aims to decide on a new drug 10 months after a 60-day filing check, so about 12 months in all, or 8 months with priority review. By our arithmetic, that puts a decision between about September 2027 and March 2028.

- Not approved anywhere as of November 20, 2026; Drugs@FDA lists no approved product.
- Lilly's stated plan: file in the first quarter of 2027, once its manufacturing data package is done.
- FDA's goal clock: 60 days to file, then 10 months standard or 6 months priority, so a decision around September 2027 to March 2028.
- Lilly and the FDA are in court over whether retatrutide is a biologic or a drug; the review clock is the same either way.

Every number checked at its primary source · Nov 20, 2026 · [22 sources](https://pepvault.app/guides/when-will-retatrutide-be-approved#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Dated facts as of November 20, 2026: Lilly's own statements, the FDA's published review goals and the court record. Trial results come from Lilly-funded phase 3 trials in adults; three are peer-reviewed, the rest are company toplines.

## Is retatrutide approved yet?

No. As of November 20, 2026, Drugs@FDA, the FDA's database of approved drugs, lists no approved retatrutide product[8](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-8). Lilly's own words, from its October 28, 2026 release: retatrutide 'has not been approved by FDA or any regulatory organization anywhere in the world', and 'anyone purporting to sell retatrutide to consumers is breaking the law'[1](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-1).

What has happened comes before approval. Six phase 3 trials, the large final-stage studies a regulator judges a drug on, have reported results since December 2025[1](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-1), and three of them are now in peer-reviewed journals[14](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-14) [15](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-15) [16](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-16). Every one met its main goal. The next step is Lilly's application, and that has not been sent yet.

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

If you're on an approved weekly GLP-1 now, PepVault logs each shot, reminds you on the day and charts your weigh-ins, so your record is ready for whoever prescribes the next step.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## When will Lilly file for FDA approval?

In the first quarter of 2027, by Lilly's own plan. On July 23, 2026, alongside the TRIUMPH-2 and TRIUMPH-3 results, Lilly wrote that it 'is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package' and plans to submit 'in Q1 2027 for U.S. approval'[2](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-2). The CMC package is the part of an application that shows the FDA how the drug is made, tested and kept stable, batch after batch, so by Lilly's account the manufacturing file, not the trials, is what remains.

Lilly repeated the plan on September 29, 2026[3](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-3), and told the federal appeals court on October 8, 2026 that it 'plans to file its application for retatrutide's approval no later than the first quarter of 2027'[4](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-4). Lilly's third-quarter report of October 29, 2026 lists the positive phase 3 trials and no filing[21](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-21), so as of November 20, 2026 the application is still to come.

## How long does the FDA take to review a new drug?

The FDA's clock has two parts. First, it has 60 days to decide whether the application is complete enough to review, called the filing date. Then, for a new molecule, its goal is to 'review and act on 90 percent of standard' applications 'within 10 months of the 60-day filing date', or within 6 months for a priority review[5](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-5). That is about 12 months from the day the application arrives, or about 8.

Priority review goes to a drug that 'would be significant improvements in the safety or effectiveness of the treatment' of a serious condition[6](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-6). Lilly has not said whether it will ask for it. A large new data set sent during the review can 'extend the goal date by three months'[5](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-5).

| Review path | Goal after the 60-day filing date | Decision if submitted Jan 1, 2027 | Decision if submitted Mar 31, 2027 |
| --- | --- | --- | --- |
| Priority review | 6 months[5](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-5) | about Sep 2, 2027 | about Nov 30, 2027 |
| Standard review | 10 months[5](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-5) | about Jan 2, 2028 | about Mar 30, 2028 |
| Standard, with a major amendment | 13 months[5](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-5) | about Apr 2, 2028 | about Jun 30, 2028 |
| National priority voucher | 1-2 month target[7](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-7) | none named for retatrutide[7](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-7) | none named for retatrutide[7](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-7) |

The dates are our arithmetic on the FDA's published goals, not a forecast from Lilly or the FDA. The FDA aims to meet each goal for 90% of applications, and an approval is never assured: the decision can also be a request for more data.

The fastest route is the FDA's national priority voucher, a pilot that targets a decision 1 to 2 months after a complete application[7](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-7). Lilly's GLP-1 pill orforglipron was awarded one in November 2025[22](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-22). None of the FDA's voucher announcements through October 2026 names retatrutide[7](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-7), and Lilly has not said it holds one, so the table plans on the normal clock.

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [FDA approval](https://pepvault.app/glossary/fda-approval)

## Why are Lilly and the FDA in court over retatrutide?

Because they disagree on what kind of product it is. Lilly asked the FDA in November 2023 to classify retatrutide as a biological product, the class that includes proteins, which is approved through a biologics license application (BLA)[9](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-9). On March 18, 2024, the FDA classified it as a drug instead, which goes through a new drug application (NDA)[9](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-9). The line is size: under FDA's rule a protein has more than 40 alpha amino acids, the standard building blocks of proteins. Lilly counts 41 units in retatrutide; the FDA counts at most 40 alpha amino acids plus one that is not[9](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-9).

1. September 30, 2025: a federal court in Indiana upheld the FDA's finding that retatrutide is not a protein, set aside its finding that retatrutide is not 'analogous' to one, and sent that question back to the agency[9](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-9).
2. February 12, 2026: Lilly appealed to the Seventh Circuit, case No. 26-1301[10](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-10).
3. September 24, 2026: the appeals court heard oral argument and asked both sides whether it can hear the appeal at all, with answers due October 8[11](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-11).
4. October 2, 2026: the FDA decided again that retatrutide is not analogous to a protein[12](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-12).
5. As of November 20, 2026: no ruling from the appeals court in the record we could read[4](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-4) [12](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-12).

For the approval date, the fight matters less than it sounds. The FDA's own court brief says that 'regardless of which statute governs, Lilly's product will be subject to a detailed FDA review process'[10](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-10), and the goals letter sets the same 10- and 6-month clocks for a new-molecule NDA and an original BLA[5](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-5). What the label changes is the business around the drug: biologics get 'a substantially longer exclusivity period before follow-on products can enter the market'[10](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-10). Lilly told the court it needs to know which pathway to file under[4](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-4). Lilly's public plan names a BLA[3](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-3); if the FDA's classification stands, retatrutide is regulated as a drug, under the law that governs new drug applications[10](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-10) [12](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-12).

## Which retatrutide trials are done, and which are still running?

ClinicalTrials.gov lists 14 phase 3 trials of retatrutide, all sponsored by Eli Lilly[17](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-17). Six have reported topline results, the first summary of a trial's main result; the others run into 2027 and beyond. Weight results are each trial's highest dose, as the source reported it. The dates are the registry's primary completion dates, when the main measurement ends, read on November 20, 2026.

| Trial | Who | Status, Nov 20, 2026 | Primary completion | Result so far |
| --- | --- | --- | --- | --- |
| TRIUMPH-4, NCT05931367 | Obesity and knee arthritis | Completed | Nov 14, 2025 | 28.7% weight loss at 68 weeks (Lilly, Dec 11, 2025)[13](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-13) |
| TRANSCEND-T2D-1, NCT06354660 | Type 2 diabetes, no other drug | Completed | Jan 22, 2026 | HbA1c down 1.94 points vs 0.81 on placebo at 40 weeks[16](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-16) |
| TRIUMPH-1, NCT05929066 | Obesity, no diabetes | Completed | Apr 6, 2026 | 25.0% weight loss at 80 weeks vs 3.9%[14](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-14) |
| TRIUMPH-3, NCT05882045 | Severe obesity and heart disease | Completed | Apr 16, 2026 | 22.6% weight loss at 80 weeks (Lilly, Jul 23, 2026)[2](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-2) |
| TRIUMPH-2, NCT05929079 | Obesity and type 2 diabetes | Completed | Jun 16, 2026 | 18.8% weight loss at 80 weeks vs 5.1%[15](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-15) |
| TRANSCEND-T2D-2, NCT06260722 | Type 2 diabetes, against Ozempic 2 mg | Active, not recruiting | Aug 27, 2026 | 20.9% weight loss vs 9.4% at 80 weeks (Lilly, Oct 28, 2026)[1](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-1) |
| TRANSCEND-T2D-3, NCT06297603 | Type 2 diabetes with kidney impairment | Active, not recruiting | Oct 26, 2026 | None published |
| TRIUMPH-5, NCT06662383 | Obesity, against tirzepatide | Active, not recruiting | Nov 2026 (estimated) | None yet[20](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-20) |
| TRIUMPH-8, NCT07232719 | Obesity, no diabetes (phase 3b) | Active, not recruiting | Jun 2027 (estimated) | None yet |
| TRIUMPH-7, NCT07035093 | Obesity and low back pain | Active, not recruiting | Sep 2027 (estimated) | None yet |
| TRIUMPH-6, NCT06859268 | Keeping weight off (phase 3b) | Active, not recruiting | Apr 2028 (estimated) | None yet |
| TRIUMPH-9, NCT07357415 | Dose step schemes (phase 3b) | Active, not recruiting | Oct 2028 (estimated) | None yet |
| TRIUMPH-Outcomes, NCT06383390 | Heart and kidney outcomes, 10,000 people | Active, not recruiting | Feb 2029 (estimated) | None yet |
| SYNERGY-Outcomes, NCT07165028 | Fatty liver disease, several drugs | Recruiting | Aug 2030 (estimated) | None yet |

Lilly's releases quote the efficacy estimand, the result had everyone stayed on the drug; the journals quote the treatment-regimen estimand, which counts everyone randomised whether or not they kept taking it, so their numbers run lower. All 14 trials are in adults.

An approval covers only the uses on its label, and the first application need not include every trial above. Lilly has not said which uses its first filing will ask for. The weight and diabetes trials were the ones complete by mid-2026, and the doses they tested are in our guide to retatrutide's trial step-ups. Our study pages at pepvault.app/research/retatrutide-triumph-1-2026 and pepvault.app/research/retatrutide-transcend-t2d-1-2026 tell those two trials in plain words.

## Is retatrutide available anywhere before approval?

Only inside Lilly's program. Its trials are the legal route, and as of November 20, 2026 the one phase 3 trial still recruiting is the fatty liver study[17](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-17). Since June 5, 2026 the registry also lists a pre-approval expanded access program: a treating physician can request it for an adult with a BMI of 35 or more despite the highest available dose of a weight drug, two or more serious obesity-related conditions and no reachable trial[19](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-19).

A pharmacy cannot make it either: the FDA writes that 'retatrutide and cagrilintide cannot be used in compounding under federal law'[18](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-18). The legal status page at pepvault.app/peptides/retatrutide/legal-status sets the FDA, DEA and WADA positions side by side, and our guide Is retatrutide safe? covers the FDA's warnings over products sold outside the trials.

## What should you watch for next?

- **TRIUMPH-5**, retatrutide against tirzepatide, reaches its primary completion in November 2026 (estimated)[20](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-20). Lilly's toplines have come one to two months after that date so far (TRIUMPH-4[13](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-13), TRANSCEND-T2D-2[1](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-1)).
- **The filing itself**, planned for the first quarter of 2027[3](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-3). The FDA's acceptance comes about 60 days later, and the goal date runs from there[5](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-5).
- **The Seventh Circuit**, on whether Lilly can appeal now and, if so, whether retatrutide is a protein[11](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-11) [12](https://pepvault.app/guides/when-will-retatrutide-be-approved#source-12).
- **The label**, if the FDA approves: the first approved dose, step schedule and uses. Until then every retatrutide dose is a trial's.

Retatrutide works on three hormone receptors, GIP, GLP-1 and glucagon, where tirzepatide works on two; pepvault.app/peptides/compare/retatrutide-vs-tirzepatide sets the two side by side. Tirzepatide is already approved, and for most people the drug that is legal today is the one to talk to a prescriber about.

<!--promo-->

If you're on an approved weekly GLP-1 now, PepVault logs each shot, reminds you on the day and charts your weigh-ins, so your record is ready for whoever prescribes the next step. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-when-will-retatrutide-be-approved-&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2), with FAQ. Press release, Oct 28, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html)
2. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3). Press release, July 23, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html)
3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. Press release, Sept 29, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-substantial-weight-loss-and-a1c-reduction-underscoring-its-potential-promise-for-people-with-obesity-and-type-2-diabetes-302891798.html)
4. Eli Lilly and Company v. Kennedy, No. 26-1301 (7th Cir.). Supplemental brief of appellant, Oct 8, 2026 (Document 47). [storage.courtlistener.com](https://storage.courtlistener.com/recap/gov.uscourts.ca7.55916/gov.uscourts.ca7.55916.47.0.pdf)
5. US Food and Drug Administration. PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027 (the PDUFA VII goals letter). [fda.gov](https://www.fda.gov/media/151712/download)
6. US Food and Drug Administration. Priority Review (content current as of Jan 4, 2018). [fda.gov](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review)
7. US Food and Drug Administration. Commissioner's National Priority Voucher (CNPV) Pilot Program (content current as of Oct 19, 2026). [fda.gov](https://www.fda.gov/CNPV)
8. US Food and Drug Administration. Drugs@FDA data (openFDA), search for retatrutide: no matches, read Nov 20, 2026. [api.fda.gov](https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:retatrutide)
9. Eli Lilly and Company v. Kennedy, No. 1:24-cv-01503-TWP-KMB (S.D. Ind.). Order on cross-motions for summary judgment, Sept 30, 2025. [govinfo.gov](https://www.govinfo.gov/content/pkg/USCOURTS-insd-1_24-cv-01503/pdf/USCOURTS-insd-1_24-cv-01503-0.pdf)
10. Eli Lilly and Company v. Kennedy, No. 26-1301 (7th Cir.). Brief for appellees (FDA and HHS), May 15, 2026 (Document 23). [storage.courtlistener.com](https://storage.courtlistener.com/recap/gov.uscourts.ca7.55916/gov.uscourts.ca7.55916.23.0.pdf)
11. Eli Lilly and Company v. Kennedy, No. 26-1301 (7th Cir.). Order directing supplemental memoranda on appellate jurisdiction, Sept 24, 2026 (Document 45). [storage.courtlistener.com](https://storage.courtlistener.com/recap/gov.uscourts.ca7.55916/gov.uscourts.ca7.55916.45.0.pdf)
12. Eli Lilly and Company v. Kennedy, No. 26-1301 (7th Cir.). Supplemental letter brief for the government, Oct 8, 2026 (Document 46). [storage.courtlistener.com](https://storage.courtlistener.com/recap/gov.uscourts.ca7.55916/gov.uscourts.ca7.55916.46.1.pdf)
13. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4). Press release, Dec 11, 2025. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html)
14. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. [PubMed 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/)
15. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. [PubMed 42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/)
16. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. [PubMed 42250575](https://pubmed.ncbi.nlm.nih.gov/42250575/)
17. ClinicalTrials.gov. Phase 3 studies of retatrutide (LY3437943), all sponsored by Eli Lilly and Company; API v2 records read Nov 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/search?intr=retatrutide&aggFilters=phase:3)
18. US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of Oct 1, 2026). [fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)
19. ClinicalTrials.gov NCT07629401. Pre-approval expanded access of retatrutide (LY3437943) (sponsor Eli Lilly and Company; first posted June 5, 2026). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629401)
20. ClinicalTrials.gov NCT06662383 (TRIUMPH-5). A study of retatrutide (LY3437943) compared to tirzepatide (LY3298176) in adults who have obesity (phase 3; sponsor Eli Lilly and Company). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06662383)
21. Eli Lilly and Company. Form 10-Q for the quarter ended Sept 30, 2026, filed Oct 29, 2026 (Compound Development). [sec.gov](https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/lly-20260930.htm)
22. US Food and Drug Administration. FDA awards second batch of national priority vouchers. Press release, Nov 6, 2025. [fda.gov](https://www.fda.gov/news-events/press-announcements/fda-awards-second-batch-national-priority-vouchers)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)

TRIUMPH-5 puts retatrutide against tirzepatide in about 800 adults. What it tests, the numbers to beat, when it should report and how to read the result.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)

  Is retatrutide safe? What its trials counted of pancreatitis, gallbladder and heart events, low blood sugar and deaths, who was left out, and what is unknown.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)

  Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

  Read the guide
- Guide · GLP-1s

  ### [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)

  No trial has tested a switch from tirzepatide to retatrutide. What each drug's trials and the Zepbound label say, how the two differ, and what is still unknown.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)

  What to expect on retatrutide week by week: the trial dose steps, when appetite drops, weight loss at weeks 24, 48 and 80, and how side effects settle.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [FDA approval](https://pepvault.app/glossary/fda-approval)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
